Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RGEN: Repligen Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Outer-limits who wrote (1)	1/21/2001 5:33:02 PM
From: Outer-limits	Respond to of 2

AMGEN news after the bell: NEW YORK, Jan 19 (Reuters) - The shares of Amgen Inc.(NASDAQ: AMGN) soared more than 20 percent in heavy after-hours tradeon Friday after a federal judge ruled that a small firm hasinfringed upon at least one of the biotech giant's patents forits blockbuster anemia drug Epogen. Amgen shares, piling on gains, last fetched $72-1/2 in theaftermarket, up a whopping 20.8 percent from their close at $60on Nasdaq. During the regular session, Amgen fell $2-1/16. By the way, this news propelled RGEN back up to 5 bucks even after the bell,(10% move)!!!